Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy

NCT ID: NCT03122782

Last Updated: 2017-06-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-01
• Study Completion Date: 2018-01-31

Brief Summary

Study Design:

Randomized Controlled Clinical Trial.

Study Population:

The study population will be a consecutive series of participants attending the Early Cancer Detection Unit (ECDU) at Ain Shams University Maternity Hospital.

80 women who are scheduled to undergo a hysteroscopic myomectomy will be included and will be randomized into two groups:

Group A: women will undergo a hysteroscopic myomectomy with the use of (TXA) Kapron in the distention medium

Group B: women will undergo hysteroscopic myomectomy with the use of placebo(normal saline in the distention medium).

Randomization will be performed using a Computer-generated randomization system.

The allocated groups will be concealed in serially-numbered sealed opaque envelopes that will only be opened after recruitment.

Patient allocation will be performed prior to the induction of anesthesia by an independent person, who will not otherwise be involved in this study.

The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium.

Therefore, this study will be a randomized double blind prospective clinical

Methodology:

1. Informed written consent obtained from the participant.

2. History

1. Personal history

2. Menstrual history

3. Detailed obstetric history

4. Surgical intervention especially uterine surgeries and any post-operative complication

5. History of drug intake, especially hormonal treatment or anticoagulant therapy.

3. Routine preoperative investigations in addition to a serum pregnancy test if pregnancy is suspected.

4. Physical examination including general, abdominal and pelvic examination.

5. Hysteroscopy will be performed in the early proliferative phase using normal saline as a distention medium.

6. Only in intervention group (TXA group) KAPRON (Tranexamic acid) will be added to the injected media.

• In intervention group 500 mg of Kapron for every 500 ml of distending media will be added.
• In the control group, placebo .i.e. ,normal saline in the same form will be injected inside every 500 ml of the distention medium.

7. The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium. Therefore, our study will be a randomized double blind prospective clinical trial.

8. Intraoperative bleeding and quality of view will be observed.

9. A blood sample will be taken from each participant in both groups after 24 hours from the end of the operation for both hemoglobin and hematocrit levels.

Types of outcome measures:

Primary outcome measures:

Estimated Blood loss defined as comparing the hematocrit and hemoglobin at base line (preoperative ) and 24 hours after surgery with the Tranexamic acid compared to the control group.

Secondary outcome measures:

The quality of view, duration of surgery, the volume of injected media, intraoperative complications and the success of the completion of the operation will be secondary outcomes.

Conditions

Surgical Blood Loss; Fibroid

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Tranexamic acid (TXA) Group

Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.

Group Type: ACTIVE_COMPARATOR

Topical application Tranexamic acid

Intervention Type: DRUG

Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy

Normal Saline (control group)

Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.

Group Type: PLACEBO_COMPARATOR

Placebo (Normal saline)

Intervention Type: DRUG

5ml of normal saline will be added to every 500 ml of distension media

Interventions

Topical application Tranexamic acid

Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy

Intervention Type: DRUG

Placebo (Normal saline)

5ml of normal saline will be added to every 500 ml of distension media

Intervention Type: DRUG

Other Intervention Names

KAPRON (AMOUN Pharmaceutical co.)

Eligibility Criteria

Inclusion Criteria

1. Subjects must be able to understand, and read and sign the study specific informed consent after fully explanation the nature of the study .

2. Subjects exhibit submucous myoma that are completely within the endometrial cavity or extend less than 50 percent into the myometrium (type 0,i)according to European Society Of Hysteroscopy (ESH).

3. The submucous myoma are less than 4 cm in diameter

Exclusion Criteria

1. Pregnancy

2. Active Pelvic Infection

3. Present or History of Cervical or Uterine Caner

4. Bleeding Diathesis or patient on anticoagulant

5. Contraindication and /or allergy to medication specified in the treatment protocol

6. History of ischemic heart disease

7. Patient with Cardiopulmonary, Hepatic , and renal diseases

8. Patient with metabolic disorders including diabetes

9. Patients with uterine septum or structural abnormality

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Ain Shams University

OTHER

Sponsor Role: lead

Responsible Party

Hajer Soliman

Resident

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ahmed Khairyy Makled, MD

Role: STUDY_CHAIR

Ain Shams University

Amgad Said Abu-Gamra, MD

Role: STUDY_CHAIR

Ain Shams University

Radwa Ali Rasheedy, MD

Role: STUDY_DIRECTOR

Ain Shams University

Hajer Giuma Soliman, M.B.B.CH

Role: PRINCIPAL_INVESTIGATOR

Ain Shams University

Central Contacts

Radwa Ali Rasheedy, MD

Role: CONTACT

Phone: 01283492979

Email: Radwaebed@yahoo.com

Other Identifiers

ASU-2016-2

Identifier Type: -

Identifier Source: org_study_id